The Impact of Subconjuctivally Injected EGF and VEGF Inhibitors on Experimental Corneal Neovascularization in Rat Model

REFERENCES

• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353–364.
   PubMed Web of Science ®Google Scholar
• Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol 2001;12:242–249.
   PubMed Web of Science ®Google Scholar
• Zhang SX, Ma JX. Ocular neovascularization: Implication of endogenous angiogenic inhibitors and potential therapy. Prog Retin Eye Res 2007;26:1–37.
   PubMed Web of Science ®Google Scholar
• Beck L Jr, D’Amore PA. Vascular development: cellular and molecular regulation. FASEB J 1997;11:365–373.
   PubMedGoogle Scholar
• Ho QT, Kuo CJ. Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 2007;39:1349–1357.
   PubMed Web of Science ®Google Scholar
• Joussen AM, Poulaki V, Mitsiades N et al. VEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci 2003;44:117–123.
   PubMedGoogle Scholar
• Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 2000;41:2514–2522.
   PubMed Web of Science ®Google Scholar
• Amano S, Rohan R, Kuroki M, Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 1998;39:18–22.
   PubMed Web of Science ®Google Scholar
• Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004;82:557–563.
   PubMedGoogle Scholar
• Kvanta A, Sarman S, Fagerholm P, Seregard S, Steen B. Expression of matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor (VEGF) in inflammation-associated corneal neovascularization. Exp Eye Res 2000;70:419–428.
   PubMed Web of Science ®Google Scholar
• Barros LF, Belfort R Jr. The effects of the subconjunctival injection of bevacizumab (Avastin) on angiogenesis in the rat cornea. An Acad Bras Cienc 2007;79:389–394.
   PubMed Web of Science ®Google Scholar
• Erdurmus M, Totan Y. Subconjunctival bevacizumab for corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2007;245:1577–1579.
   PubMed Web of Science ®Google Scholar
• Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol 2008;145:424–431.
   PubMedGoogle Scholar
• Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Dagli O, Durukan AH. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea 2008;27:357–362.
   PubMedGoogle Scholar
• Kim R, Toge T. Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents. Surg Today 2004;34:293–303.
   Google Scholar
• Baker CH, Kedar D, McCarty MF et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002;161:929–938.
   PubMed Web of Science ®Google Scholar
• Güler M, Yilmaz T, Ozercan I, Elkiran T. The inhibitory effects of trastuzumab on corneal neovascularization. Am J Ophthalmol 2009;147:703–708.e2.
   Google Scholar
• Mahoney JM, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 1985;4:531–535.
   PubMed Web of Science ®Google Scholar
• Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 2006;90:1542–1547.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Damico L, Shams N, Lowman H, Kim R. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina (Philadelphia, Pa) 2006;26:859–870.
   PubMed Web of Science ®Google Scholar
• Dib E, Rodrigues EB, Maia M et al. [Vital dyes in chromovitrectomy]. Arq Bras Oftalmol 2009;72:845–850.
   PubMedGoogle Scholar
• Lin RC, Rosenfeld PJ. Antiangiogenic therapy in neovascular age-related macular degeneration. Int Ophthalmol Clin 2007;47:117–137.
   Google Scholar
• You IC, Kang IS, Lee SH, Yoon KC. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol 2009;87:653–658.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–2816.
   PubMed Web of Science ®Google Scholar
• Eyetech Study Group. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 2002;22:143–152.
   PubMed Web of Science ®Google Scholar
• Ishida S, Usui T, Yamashiro K et al. VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003;198:483–489.
   PubMed Web of Science ®Google Scholar
• Ma DH, Chen JK, Zhang F, Lin KY, Yao JY, Yu JS. Regulation of corneal angiogenesis in limbal stem cell deficiency. Prog Retin Eye Res 2006;25:563–590.
   PubMedGoogle Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299–309.
   PubMed Web of Science ®Google Scholar
• Spitzer MS, Yoeruek E, Sierra A et al. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells. Graefes Arch Clin Exp Ophthalmol 2007;245:1837–1842.
   PubMed Web of Science ®Google Scholar
• Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefes Arch Clin Exp Ophthalmol 2009;247:171–177.
   PubMed Web of Science ®Google Scholar
• Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 2011;12:173–181.
   PubMed Web of Science ®Google Scholar
• Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31–53.
   PubMed Web of Science ®Google Scholar
• Ono M, Kuwano M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006;12:7242–7251.
   PubMed Web of Science ®Google Scholar
• Guan H, Jia SF, Zhou Z, Stewart J, Kleinerman ES. Herceptin down-regulates HER-2/neu and vascular endothelial growth factor expression and enhances taxol-induced cytotoxicity of human Ewing’s sarcoma cells in vitro and in vivo. Clin Cancer Res 2005;11:2008–2017.
   PubMed Web of Science ®Google Scholar
• Klos KS, Zhou X, Lee S et al. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 2003;98:1377–1385.
   PubMed Web of Science ®Google Scholar
• Nahtaa R, Esteva FC. Herceptin: mechanisms of action and resistance. Cancer Letters. 2006; 232: 123–138
   Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211–225.
   PubMed Web of Science ®Google Scholar
• Yen L, You XL, Al Moustafa AE et al. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis. Oncogene 2000;19:3460–3469.
   PubMed Web of Science ®Google Scholar
• Lane HA, Motoyama AB. Modulation of p27/Cdk2 complex formation through 4D5-mediated inhibition of HER2 receptor signaling. Ann Oncol. 2001; 12: 21–22
   Web of Science ®Google Scholar
• Mayfield S, Vaughn JP, Kute TE. DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines. Breast Cancer Res Treat 2001;70:123–129.
   PubMedGoogle Scholar
• Cooley S, Burns LJ, Repka T, Miller JS. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999;27:1533–1541.
   PubMed Web of Science ®Google Scholar
• Mohsin SK, Weiss HL, Gutierrez MC et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005;23:2460–2468.
   PubMed Web of Science ®Google Scholar
• Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004;14:433–439.
   PubMed Web of Science ®Google Scholar
• Edelman JL, Castro MR, Wen Y. Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea. Invest Ophthalmol Vis Sci 1999;40:1112–1123.
   PubMed Web of Science ®Google Scholar
• Bock F, Onderka J, Dietrich T et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007;48:2545–2552.
   PubMed Web of Science ®Google Scholar
• Oh JY, Kim MK, Shin MS, Lee HJ, Lee JH, Wee WR. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr Eye Res 2009;34:85–91.
   PubMed Web of Science ®Google Scholar
• Cursiefen C, Claus M. Kuchle. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1988;17:611–613
   Google Scholar
• Blotnıck S, Peopless GE. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: Differential production and release by CD4+ and CD8+ T cells. Cell Biol 1994;91:2890–2894
   Google Scholar
• Dorey CK, Aouididi S. Correlation of vascular permeability factor/vascular endothelial growth factor with extraretinal neovascularization in the rat. Arch Human Ewing’s sarcoma cells in vitro and in vivo. Clinical Can Res 2005;11:2008–2017.
   Google Scholar